Sp733
EFFECTIVE ADVOCACY ACROSS PARTY LINES: WHAT TO DO WHEN YOU DON'T LIKE YOUR MEMBER OF CONGRESS
Date
May 8, 2023
Explore related products in the following collection:
Society: AGA
This session will provide attendees with an overview of physician advocacy, how it impacts the GI community and how to get involved. We will discuss AGA advocacy priorities, a model for removing barriers to high-value care in inflammatory bowel disease and GI, and how to most effectively engage in collaborative advocacy on behalf of the GI community.
This session will provide attendees with an overview of physician advocacy, how it impacts the GI community and how to get involved. We will discuss AGA advocacy priorities, a model for removing barriers to high-value care in inflammatory bowel disease and GI, and how to most effectively engage in collaborative advocacy on behalf of the GI community.
Presenter
University of Pennsylvania
Tracks
Related Products
MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
PANEL DISCUSSION
This session will provide attendees with an overview of physician advocacy, how it impacts the GI community and how to get involved…
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
Q&A
This session is designed to demonstrate successful quality improvement in practices and across institutions with the focus on and meaningful real world implementation across a range of GI conditions…
